Chemotherapy-Induced Anemia and Oncologist Perception on Treatment: Results of a Web-Based Survey

Aims and background Anemia prevalence and incidence in chemotherapy-treated patients is high. Erythropoiesis-stimulating agents (ESAs) are frequently employed in the management of chemotherapy-induced anemia. However, other treatments such as red blood transfusion or iron supplementation are normall...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Tumori 2013, Vol.99 (1), p.45-50
Hauptverfasser: Cortinovis, Diego, Beretta, Giordano, Piazza, Elena, Luchena, Giovanna, Aglione, Stefania, Bertolini, Alessandro, Buzzoni, Roberto, Cabiddu, Mary, Carnaghi, Carlo, Danova, Marco, Farina, Gabriella, Ferrari, Vittorio, Frascaroli, Mara, Reni, Michele, Tansini, Giuseppe
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 50
container_issue 1
container_start_page 45
container_title Tumori
container_volume 99
creator Cortinovis, Diego
Beretta, Giordano
Piazza, Elena
Luchena, Giovanna
Aglione, Stefania
Bertolini, Alessandro
Buzzoni, Roberto
Cabiddu, Mary
Carnaghi, Carlo
Danova, Marco
Farina, Gabriella
Ferrari, Vittorio
Frascaroli, Mara
Reni, Michele
Tansini, Giuseppe
description Aims and background Anemia prevalence and incidence in chemotherapy-treated patients is high. Erythropoiesis-stimulating agents (ESAs) are frequently employed in the management of chemotherapy-induced anemia. However, other treatments such as red blood transfusion or iron supplementation are normally used. Recent international guidelines raised some concern about ESAs employment with a possible impact in chemotherapy-induced anemia management and changes in clinical practice behavior. Methods To evaluate opinions about chemotherapy-induced anemia clinical management preference, the Associazione Italiana Oncologia Medica (AIOM) Lombardy section coordinators sent via email a 12-item questionnaire about their knowledge on CIA and usual therapeutic strategies to manage this adverse event to AIOM Lombardy onco-hematologist members. Results From January 2011 to March 2011, 81 questionnaires were collected with an approximated share of 30%. The survey was completed mainly by oncologists (91%) aged 35–50 years (50%). Chemotherapy-induced anemia was considered to have clinical impact in changing cancer therapeutic strategy by nearly 60% of the respondents. ESAs were administered largely (80%) with concomitant iron supplementation in 52%; 38% jointly used blood transfusion as part of the therapy. Nearly 20% of those who replied correctly employed transferrin saturation levels as a marker to guide iron supplementation. Physician prescribers strictly followed the guidelines to start and stop ESAs even if 14% were negatively influenced by new ASCO recommendations. ESA biosimilars were considered future substitutes of originators in 45% of the cases. Conclusions Chemotherapy-induced anemia was perceived as an adverse event with a mild impact on clinical practice. ESAs were largely employed, however the number of transfusions and lack of employment of markers of iron depletion suggested that adherence to guidelines could be theoretically met but with some discordances regarding the most appropriate strategies in daily clinical practice.
doi_str_mv 10.1177/030089161309900108
format Article
fullrecord <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1177_030089161309900108</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_030089161309900108</sage_id><sourcerecordid>10.1177_030089161309900108</sourcerecordid><originalsourceid>FETCH-LOGICAL-c287t-d3c62ccedbe6347ead013c986be52edd2337dc18277c23fe03fd6d8d428b99083</originalsourceid><addsrcrecordid>eNp9kEFLAzEQhYMoWKt_wFP-QOwkaTdZb7VoLRQqWvG4ZJPZdks3Kcmu0H_vlnoThIG5vO_NvEfIPYcHzpUagQTQOc-4hDwH4KAvyECA1ExMRH5JBicBOymuyU1KO4AxiCwbEDPbYhPaLUZzOLKFd51FR6cem9pQ4x1deRv2YVOnlr5htHho6-BpP-uIpm3Qt4_0HVO3bxMNFTX0C0v2ZFLv8tHFbzzekqvK7BPe_e4h-Xx5Xs9e2XI1X8ymS2aFVi1z0mbC9sdLzORYoXHApc11VuJEoHNCSuUs10IpK2SFICuXOe3GQpd9ZC2HRJx9bQwpRayKQ6wbE48Fh-JUUvG3pB4anaFkNljsQhd9_-N_xA_CSmgS</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Chemotherapy-Induced Anemia and Oncologist Perception on Treatment: Results of a Web-Based Survey</title><source>SAGE Complete A-Z List</source><creator>Cortinovis, Diego ; Beretta, Giordano ; Piazza, Elena ; Luchena, Giovanna ; Aglione, Stefania ; Bertolini, Alessandro ; Buzzoni, Roberto ; Cabiddu, Mary ; Carnaghi, Carlo ; Danova, Marco ; Farina, Gabriella ; Ferrari, Vittorio ; Frascaroli, Mara ; Reni, Michele ; Tansini, Giuseppe</creator><creatorcontrib>Cortinovis, Diego ; Beretta, Giordano ; Piazza, Elena ; Luchena, Giovanna ; Aglione, Stefania ; Bertolini, Alessandro ; Buzzoni, Roberto ; Cabiddu, Mary ; Carnaghi, Carlo ; Danova, Marco ; Farina, Gabriella ; Ferrari, Vittorio ; Frascaroli, Mara ; Reni, Michele ; Tansini, Giuseppe ; on behalf of AIOM Lombardia</creatorcontrib><description>Aims and background Anemia prevalence and incidence in chemotherapy-treated patients is high. Erythropoiesis-stimulating agents (ESAs) are frequently employed in the management of chemotherapy-induced anemia. However, other treatments such as red blood transfusion or iron supplementation are normally used. Recent international guidelines raised some concern about ESAs employment with a possible impact in chemotherapy-induced anemia management and changes in clinical practice behavior. Methods To evaluate opinions about chemotherapy-induced anemia clinical management preference, the Associazione Italiana Oncologia Medica (AIOM) Lombardy section coordinators sent via email a 12-item questionnaire about their knowledge on CIA and usual therapeutic strategies to manage this adverse event to AIOM Lombardy onco-hematologist members. Results From January 2011 to March 2011, 81 questionnaires were collected with an approximated share of 30%. The survey was completed mainly by oncologists (91%) aged 35–50 years (50%). Chemotherapy-induced anemia was considered to have clinical impact in changing cancer therapeutic strategy by nearly 60% of the respondents. ESAs were administered largely (80%) with concomitant iron supplementation in 52%; 38% jointly used blood transfusion as part of the therapy. Nearly 20% of those who replied correctly employed transferrin saturation levels as a marker to guide iron supplementation. Physician prescribers strictly followed the guidelines to start and stop ESAs even if 14% were negatively influenced by new ASCO recommendations. ESA biosimilars were considered future substitutes of originators in 45% of the cases. Conclusions Chemotherapy-induced anemia was perceived as an adverse event with a mild impact on clinical practice. ESAs were largely employed, however the number of transfusions and lack of employment of markers of iron depletion suggested that adherence to guidelines could be theoretically met but with some discordances regarding the most appropriate strategies in daily clinical practice.</description><identifier>ISSN: 0300-8916</identifier><identifier>EISSN: 2038-2529</identifier><identifier>DOI: 10.1177/030089161309900108</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><ispartof>Tumori, 2013, Vol.99 (1), p.45-50</ispartof><rights>2013 SAGE Publications</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c287t-d3c62ccedbe6347ead013c986be52edd2337dc18277c23fe03fd6d8d428b99083</citedby><cites>FETCH-LOGICAL-c287t-d3c62ccedbe6347ead013c986be52edd2337dc18277c23fe03fd6d8d428b99083</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/030089161309900108$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/030089161309900108$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,777,781,4010,21800,27904,27905,27906,43602,43603</link.rule.ids></links><search><creatorcontrib>Cortinovis, Diego</creatorcontrib><creatorcontrib>Beretta, Giordano</creatorcontrib><creatorcontrib>Piazza, Elena</creatorcontrib><creatorcontrib>Luchena, Giovanna</creatorcontrib><creatorcontrib>Aglione, Stefania</creatorcontrib><creatorcontrib>Bertolini, Alessandro</creatorcontrib><creatorcontrib>Buzzoni, Roberto</creatorcontrib><creatorcontrib>Cabiddu, Mary</creatorcontrib><creatorcontrib>Carnaghi, Carlo</creatorcontrib><creatorcontrib>Danova, Marco</creatorcontrib><creatorcontrib>Farina, Gabriella</creatorcontrib><creatorcontrib>Ferrari, Vittorio</creatorcontrib><creatorcontrib>Frascaroli, Mara</creatorcontrib><creatorcontrib>Reni, Michele</creatorcontrib><creatorcontrib>Tansini, Giuseppe</creatorcontrib><creatorcontrib>on behalf of AIOM Lombardia</creatorcontrib><title>Chemotherapy-Induced Anemia and Oncologist Perception on Treatment: Results of a Web-Based Survey</title><title>Tumori</title><description>Aims and background Anemia prevalence and incidence in chemotherapy-treated patients is high. Erythropoiesis-stimulating agents (ESAs) are frequently employed in the management of chemotherapy-induced anemia. However, other treatments such as red blood transfusion or iron supplementation are normally used. Recent international guidelines raised some concern about ESAs employment with a possible impact in chemotherapy-induced anemia management and changes in clinical practice behavior. Methods To evaluate opinions about chemotherapy-induced anemia clinical management preference, the Associazione Italiana Oncologia Medica (AIOM) Lombardy section coordinators sent via email a 12-item questionnaire about their knowledge on CIA and usual therapeutic strategies to manage this adverse event to AIOM Lombardy onco-hematologist members. Results From January 2011 to March 2011, 81 questionnaires were collected with an approximated share of 30%. The survey was completed mainly by oncologists (91%) aged 35–50 years (50%). Chemotherapy-induced anemia was considered to have clinical impact in changing cancer therapeutic strategy by nearly 60% of the respondents. ESAs were administered largely (80%) with concomitant iron supplementation in 52%; 38% jointly used blood transfusion as part of the therapy. Nearly 20% of those who replied correctly employed transferrin saturation levels as a marker to guide iron supplementation. Physician prescribers strictly followed the guidelines to start and stop ESAs even if 14% were negatively influenced by new ASCO recommendations. ESA biosimilars were considered future substitutes of originators in 45% of the cases. Conclusions Chemotherapy-induced anemia was perceived as an adverse event with a mild impact on clinical practice. ESAs were largely employed, however the number of transfusions and lack of employment of markers of iron depletion suggested that adherence to guidelines could be theoretically met but with some discordances regarding the most appropriate strategies in daily clinical practice.</description><issn>0300-8916</issn><issn>2038-2529</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><recordid>eNp9kEFLAzEQhYMoWKt_wFP-QOwkaTdZb7VoLRQqWvG4ZJPZdks3Kcmu0H_vlnoThIG5vO_NvEfIPYcHzpUagQTQOc-4hDwH4KAvyECA1ExMRH5JBicBOymuyU1KO4AxiCwbEDPbYhPaLUZzOLKFd51FR6cem9pQ4x1deRv2YVOnlr5htHho6-BpP-uIpm3Qt4_0HVO3bxMNFTX0C0v2ZFLv8tHFbzzekqvK7BPe_e4h-Xx5Xs9e2XI1X8ymS2aFVi1z0mbC9sdLzORYoXHApc11VuJEoHNCSuUs10IpK2SFICuXOe3GQpd9ZC2HRJx9bQwpRayKQ6wbE48Fh-JUUvG3pB4anaFkNljsQhd9_-N_xA_CSmgS</recordid><startdate>2013</startdate><enddate>2013</enddate><creator>Cortinovis, Diego</creator><creator>Beretta, Giordano</creator><creator>Piazza, Elena</creator><creator>Luchena, Giovanna</creator><creator>Aglione, Stefania</creator><creator>Bertolini, Alessandro</creator><creator>Buzzoni, Roberto</creator><creator>Cabiddu, Mary</creator><creator>Carnaghi, Carlo</creator><creator>Danova, Marco</creator><creator>Farina, Gabriella</creator><creator>Ferrari, Vittorio</creator><creator>Frascaroli, Mara</creator><creator>Reni, Michele</creator><creator>Tansini, Giuseppe</creator><general>SAGE Publications</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>2013</creationdate><title>Chemotherapy-Induced Anemia and Oncologist Perception on Treatment: Results of a Web-Based Survey</title><author>Cortinovis, Diego ; Beretta, Giordano ; Piazza, Elena ; Luchena, Giovanna ; Aglione, Stefania ; Bertolini, Alessandro ; Buzzoni, Roberto ; Cabiddu, Mary ; Carnaghi, Carlo ; Danova, Marco ; Farina, Gabriella ; Ferrari, Vittorio ; Frascaroli, Mara ; Reni, Michele ; Tansini, Giuseppe</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c287t-d3c62ccedbe6347ead013c986be52edd2337dc18277c23fe03fd6d8d428b99083</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cortinovis, Diego</creatorcontrib><creatorcontrib>Beretta, Giordano</creatorcontrib><creatorcontrib>Piazza, Elena</creatorcontrib><creatorcontrib>Luchena, Giovanna</creatorcontrib><creatorcontrib>Aglione, Stefania</creatorcontrib><creatorcontrib>Bertolini, Alessandro</creatorcontrib><creatorcontrib>Buzzoni, Roberto</creatorcontrib><creatorcontrib>Cabiddu, Mary</creatorcontrib><creatorcontrib>Carnaghi, Carlo</creatorcontrib><creatorcontrib>Danova, Marco</creatorcontrib><creatorcontrib>Farina, Gabriella</creatorcontrib><creatorcontrib>Ferrari, Vittorio</creatorcontrib><creatorcontrib>Frascaroli, Mara</creatorcontrib><creatorcontrib>Reni, Michele</creatorcontrib><creatorcontrib>Tansini, Giuseppe</creatorcontrib><creatorcontrib>on behalf of AIOM Lombardia</creatorcontrib><collection>CrossRef</collection><jtitle>Tumori</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cortinovis, Diego</au><au>Beretta, Giordano</au><au>Piazza, Elena</au><au>Luchena, Giovanna</au><au>Aglione, Stefania</au><au>Bertolini, Alessandro</au><au>Buzzoni, Roberto</au><au>Cabiddu, Mary</au><au>Carnaghi, Carlo</au><au>Danova, Marco</au><au>Farina, Gabriella</au><au>Ferrari, Vittorio</au><au>Frascaroli, Mara</au><au>Reni, Michele</au><au>Tansini, Giuseppe</au><aucorp>on behalf of AIOM Lombardia</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chemotherapy-Induced Anemia and Oncologist Perception on Treatment: Results of a Web-Based Survey</atitle><jtitle>Tumori</jtitle><date>2013</date><risdate>2013</risdate><volume>99</volume><issue>1</issue><spage>45</spage><epage>50</epage><pages>45-50</pages><issn>0300-8916</issn><eissn>2038-2529</eissn><abstract>Aims and background Anemia prevalence and incidence in chemotherapy-treated patients is high. Erythropoiesis-stimulating agents (ESAs) are frequently employed in the management of chemotherapy-induced anemia. However, other treatments such as red blood transfusion or iron supplementation are normally used. Recent international guidelines raised some concern about ESAs employment with a possible impact in chemotherapy-induced anemia management and changes in clinical practice behavior. Methods To evaluate opinions about chemotherapy-induced anemia clinical management preference, the Associazione Italiana Oncologia Medica (AIOM) Lombardy section coordinators sent via email a 12-item questionnaire about their knowledge on CIA and usual therapeutic strategies to manage this adverse event to AIOM Lombardy onco-hematologist members. Results From January 2011 to March 2011, 81 questionnaires were collected with an approximated share of 30%. The survey was completed mainly by oncologists (91%) aged 35–50 years (50%). Chemotherapy-induced anemia was considered to have clinical impact in changing cancer therapeutic strategy by nearly 60% of the respondents. ESAs were administered largely (80%) with concomitant iron supplementation in 52%; 38% jointly used blood transfusion as part of the therapy. Nearly 20% of those who replied correctly employed transferrin saturation levels as a marker to guide iron supplementation. Physician prescribers strictly followed the guidelines to start and stop ESAs even if 14% were negatively influenced by new ASCO recommendations. ESA biosimilars were considered future substitutes of originators in 45% of the cases. Conclusions Chemotherapy-induced anemia was perceived as an adverse event with a mild impact on clinical practice. ESAs were largely employed, however the number of transfusions and lack of employment of markers of iron depletion suggested that adherence to guidelines could be theoretically met but with some discordances regarding the most appropriate strategies in daily clinical practice.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><doi>10.1177/030089161309900108</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0300-8916
ispartof Tumori, 2013, Vol.99 (1), p.45-50
issn 0300-8916
2038-2529
language eng
recordid cdi_crossref_primary_10_1177_030089161309900108
source SAGE Complete A-Z List
title Chemotherapy-Induced Anemia and Oncologist Perception on Treatment: Results of a Web-Based Survey
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T04%3A42%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chemotherapy-Induced%20Anemia%20and%20Oncologist%20Perception%20on%20Treatment:%20Results%20of%20a%20Web-Based%20Survey&rft.jtitle=Tumori&rft.au=Cortinovis,%20Diego&rft.aucorp=on%20behalf%20of%20AIOM%20Lombardia&rft.date=2013&rft.volume=99&rft.issue=1&rft.spage=45&rft.epage=50&rft.pages=45-50&rft.issn=0300-8916&rft.eissn=2038-2529&rft_id=info:doi/10.1177/030089161309900108&rft_dat=%3Csage_cross%3E10.1177_030089161309900108%3C/sage_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_sage_id=10.1177_030089161309900108&rfr_iscdi=true